Recent Transactions

14-Feb-24
Undisclosed
United Kingdom flag
Target: 

Huntswood CTC Limited

Acquiror: 
The Results Companies, LLC

Advised Huntswood CTC Limited, a business process and outsourcing company, on its sale to The Results Companies, LLC (“ResultsCX”), a global Customer Experience Management company backed by ChrysCapital

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

13-Jul-23
$224 million
Target: 

Distribuidora Internacional Carmen SAU

United States flag
Acquiror: 
Diploma PLC

Advised Diploma PLC in the acquisition of  Distribuidora Internacional Carmen SAU (“DICSA”),  a market-leading distributor of fluid power solutions into the European aftermarket

01-Jun-23
$90.4 million
Canada flag
Target: 

PCAS Canada Inc.

Japan flag
Acquiror: 
DIC Corporation

Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens

27-Apr-23
$403 million
Netherlands flag
Target: 

Distrelec BV

United Kingdom flag
Acquiror: 
RS Group plc

Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

07-Mar-23
Undisclosed
United Kingdom flag
Target: 

David Brown Santasalo

United States flag
Acquiror: 
Stellex Capital Management

Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

28-Dec-22
Pending
Undisclosed
Japan flag
Target: 

Eisai Distribution Co., Ltd.

Japan flag
Acquiror: 
Yasuda Logistics Corporation

Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.

24-Nov-22
Pending
Undisclosed
Target: 

Kyowa Kirin International’s established medicines business

Germany flag
Acquiror: 
Grünenthal

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

28-Jul-22
Pending
$1.6 billion
Chile Flag
Target: 

Derco Holdings

United Kingdom flag
Acquiror: 
Inchcape Plc

Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America

04-Jul-22
$270 million
France flag
Target: 

Vulcanic

United Kingdom flag
Acquiror: 
Spirax-Sarco Engineering plc

Advised Spirax-Sarco Engineering plc, a thermal energy management and niche pumping specialist, on the $270m acquisition of Vulcanic, a French industrial electric heating group and the largest supplier in Europe of bespoke industrial electric heating solutions

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

07-Dec-21
$153 million
Japan flag
Target: 

Japan Medical Dynamic Marketing

Japan flag
Acquiror: 
Mitsui Chemicals

Advising Mitsui Chemicals,  one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG

05-Oct-21
$175 million
United Kingdom flag
Target: 

Kao Data Ltd

New Zealand flag
Acquiror: 
Infratil Ltd

Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform

09-Sep-21
$2.1 billion
United Kingdom flag
Target: 

easyJet plc

flag not available
Acquiror: 
N/A

Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF

27-Jul-21
Undisclosed
United Kingdom flag
Target: 

Pulsant Limited

France flag
Acquiror: 
Antin Infrastructure Partners

Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services

14-Jul-21
Undisclosed
Target: 

New Day Aluminum LLC

United Kingdom flag
Acquiror: 
Concord Resources Ltd.

Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.

01-Jul-21
$180 million
United Kingdom flag
Target: 

British Council’s Indian IELTS operations

Australia flag
Acquiror: 
IDP Education Limited

Sole financial adviser to IDP Education, a co-owner and distributor of the IELTS English language test, on the acquisition of the British Council’s Indian IELTS operations

27-May-21
$1.4 billion
United Kingdom flag
Target: 

Equiniti Group PLC

United States flag
Acquiror: 
Siris Capital Group LLC

Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

29-Dec-20
$110 million
United States flag
Target: 

Biogix, Inc.

United Kingdom flag
Acquiror: 
Alliance Pharma plc

Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc

01-Oct-20
$2.6 billion
United Kingdom flag
Target: 

Rolls-Royce £2bn Fully Underwritten Rights Issue

flag not available
Acquiror: 
N/A

Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package

Pages

show all